Literature DB >> 7504722

Intraseptal galanin potentiates scopolamine impairment of delayed nonmatching to sample.

J K Robinson1, J N Crawley.   

Abstract

Galanin coexists with ACh in the basal forebrain and medial septal region. The present study investigated the interactions of the muscarinic receptor antagonist scopolamine and the neuropeptide galanin on an operant spatial delayed non-matching to sample task (DNMTS) in rats. Scopolamine administered both intraperitoneally and microinjected into the medial septum impaired performance on DNMTS. Galanin administered alone into the medial septum did not disrupt DNMTS, but potentiated the disruptive effects of intraperitoneal administered scopolamine. These findings raise the possibility that endogenous galanin may exacerbate cognitive impairments associated with forebrain cholinergic deficits.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504722      PMCID: PMC6576416     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  6 in total

Review 1.  Galanin--a neuropeptide with inhibitory actions.

Authors:  K Kask; U Langel; T Bartfai
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

Review 2.  Galanin-acetylcholine interactions in rodent memory tasks and Alzheimer's disease.

Authors:  M P McDonald; J N Crawley
Journal:  J Psychiatry Neurosci       Date:  1997-11       Impact factor: 6.186

Review 3.  Neuroprotective role for galanin in Alzheimer's disease.

Authors:  Scott E Counts; Sylvia E Perez; Stephen D Ginsberg; Elliott J Mufson
Journal:  Exp Suppl       Date:  2010

Review 4.  In search of the neurobiological underpinnings of the differential outcomes effect.

Authors:  L M Savage
Journal:  Integr Physiol Behav Sci       Date:  2001 Jul-Sep

Review 5.  Galanin impairs cognitive abilities in rodents: relevance to Alzheimer's disease.

Authors:  J N Crawley
Journal:  Cell Mol Life Sci       Date:  2008-06       Impact factor: 9.261

Review 6.  Galanin in Alzheimer's disease: neuroinhibitory or neuroprotective?

Authors:  S E Counts; S E Perez; E J Mufson
Journal:  Cell Mol Life Sci       Date:  2008-06       Impact factor: 9.261

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.